加纳贫困城市地区 2 型糖尿病和高血压合并症护理的家庭经济负担:一项混合方法研究。
Household economic burden of type-2 diabetes and hypertension comorbidity care in urban-poor Ghana: a mixed methods study.
机构信息
Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Department of Health Policy, Planning and Management, School of Public Health, University of Ghana, P.O. Box LG 13, Legon, Accra, Ghana.
出版信息
BMC Health Serv Res. 2024 Sep 5;24(1):1028. doi: 10.1186/s12913-024-11516-9.
BACKGROUND
Non-communicable diseases (NCDs) predispose households to exorbitant healthcare expenditures in health systems where there is no access to effective financial protection for healthcare. This study assessed the economic burden associated with the rising burden of type-2 diabetes (T2D) and hypertension comorbidity management, and its implications for healthcare seeking in urban Accra.
METHODS
A convergent parallel mixed-methods study design was used. Quantitative sociodemographic and cost data were collected through survey from a random community-based sample of 120 adults aged 25 years and older and living with comorbid T2D and hypertension in Ga Mashie, Accra, Ghana in November and December 2022. The monthly economic cost of T2D and hypertension comorbidity care was estimated using a descriptive cost-of-illness analysis technique from the perspective of patients. Thirteen focus group discussions (FGDs) were conducted among community members with and without comorbid T2D and hypertension. The FGDs were analysed using deductive and inductive thematic approaches. Findings from the survey and qualitative study were integrated in the discussion.
RESULTS
Out of a total of 120 respondents who self-reported comorbid T2D and hypertension, 23 (19.2%) provided complete healthcare cost data. The direct cost of managing T2D and hypertension comorbidity constituted almost 94% of the monthly economic cost of care, and the median direct cost of care was US$19.30 (IQR:10.55-118.88). Almost a quarter of the respondents pay for their healthcare through co-payment and insurance jointly, and 42.9% pay out-of-pocket (OOP). Patients with lower socioeconomic status incurred a higher direct cost burden compared to those in the higher socioeconomic bracket. The implications of the high economic burden resulting from self-funding of healthcare were found from the qualitative study to be: 1) poor access to quality healthcare; (2) poor medication adherence; (3) aggravated direct non-medical and indirect cost; and (4) psychosocial support to help cope with the cost burden.
CONCLUSION
The economic burden associated with healthcare in instances of comorbid T2D and hypertension can significantly impact household budget and cause financial difficulty or impoverishment. Policies targeted at effectively managing NCDs should focus on strengthening a comprehensive and reliable National Health Insurance Scheme coverage for care of chronic conditions.
背景
在没有获得有效医疗保健财务保障的卫生系统中,非传染性疾病(NCDs)使家庭面临过高的医疗支出。本研究评估了 2 型糖尿病(T2D)和高血压合并症管理负担不断增加所带来的经济负担,以及其对加纳阿克拉市 Ga Mashie 社区 120 名年龄在 25 岁及以上、患有 T2D 和高血压合并症的成年人寻求医疗保健的影响。
方法
采用 convergent parallel 混合方法设计。通过对加纳阿克拉 Ga Mashie 社区的 120 名年龄在 25 岁及以上、患有 T2D 和高血压合并症的成年人进行随机社区样本调查,收集了定量的社会人口学和成本数据。采用疾病成本分析技术,从患者角度估算了 T2D 和高血压合并症护理的每月经济成本。在加纳阿克拉 Ga Mashie 社区进行了 13 次有合并 T2D 和高血压的社区成员和无合并 T2D 和高血压的社区成员的焦点小组讨论(FGD)。使用演绎和归纳主题方法对 FGD 进行了分析。将调查和定性研究的结果纳入讨论。
结果
在 120 名自我报告患有 T2D 和高血压合并症的受访者中,有 23 名(19.2%)提供了完整的医疗费用数据。管理 T2D 和高血压合并症的直接成本占护理月经济成本的近 94%,护理直接成本中位数为 19.30 美元(IQR:10.55-118.88)。近四分之一的受访者通过共同支付和保险联合支付医疗费用,42.9%的人自掏腰包(OOP)。与社会经济地位较高的人相比,社会经济地位较低的人承担的直接成本负担更高。从定性研究中发现,自我出资医疗的高经济负担的影响是:1)获得优质医疗服务的机会较差;2)药物依从性差;3)直接非医疗和间接成本加重;4)社会心理支持以帮助应对经济负担。
结论
T2D 和高血压合并症的医疗保健相关经济负担可能会对家庭预算产生重大影响,并导致经济困难或贫困。针对 NCDs 的管理制定的政策应侧重于加强全面可靠的国家健康保险计划,以覆盖慢性病的护理。
相似文献
Ghana Med J. 2012-6
BMC Health Serv Res. 2024-10-14
Glob Health Action. 2020-12-31
Eur J Epidemiol. 2014-12-21
BMC Int Health Hum Rights. 2017-5-22
Int J Equity Health. 2017-1-14
引用本文的文献
Front Med (Lausanne). 2025-6-2
本文引用的文献
PLOS Glob Public Health. 2024-3-12
J Health Econ Outcomes Res. 2023-3-17
Nat Rev Dis Primers. 2022-7-14
Lancet Reg Health Am. 2022-2